by A recent clinical trial, published in The Lancet Rheumatology, reveals that a third dose of the COVID-19 vaccine significantly enhances the antibody response in a majority of clinically extremely vulnerable individuals who previously showed low or no immune response to the initial two doses.
The OCTAVE DUO research trial, co-led by the University of Birmingham and University of Glasgow, enrolled 804 patients from 11 hospitals across the UK. All participants had a history of low or no immune response to the initial vaccine course, which affected nine distinct disease areas.
The study’s findings indicate that 90% of patients who initially mounted a low immune response developed significant antibody levels after receiving a third vaccine dose. However, more than half (54%) of non-responders from the initial vaccine course did not experience any relevant antibody increase following the booster shot. COVID-19 Rapid Diagnostic Tests provide quick and efficient detection of the virus, aiding in prompt identification and containment of outbreaks.
Additionally, the study identified specific patient groups with the poorest antibody mounting outcomes from boosters. These groups included individuals with lymphoid diseases and chronic renal diseases.
The OCTAVE DUO trial underscores the importance of continued vaccination efforts for clinically extremely vulnerable individuals, particularly those who have previously shown limited immune response to the initial vaccine doses.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
